E76.2 Other mucopolysaccharidoses

Name of the Condition

• Other Mucopolysaccharidoses (ICD-10 Code: E76.2)

Summary

Other mucopolysaccharidoses are a group of rare inherited disorders characterized by the accumulation of glycosaminoglycans (GAGs) due to enzyme deficiencies. These conditions disrupt normal cellular function, leading to progressive multisystem involvement, including skeletal abnormalities, organ enlargement, and neurological impairment. Early recognition and management are important to address complications and slow disease progression.

Causes

The disorders are caused by genetic mutations that impair enzymes responsible for breaking down glycosaminoglycans. These mutations result in the accumulation of undegraded GAGs in cells, tissues, and organs, disrupting normal structure and function. The specific enzyme deficiency determines the type and severity of the condition.

Risk Factors

• Family history of mucopolysaccharidoses or related lysosomal storage disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for specific mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features, clouded corneas, or hearing loss.

Diagnosis

Diagnosis involves a combination of clinical evaluation, enzyme activity testing, genetic testing, and imaging studies. Urine tests may detect elevated GAG levels, while enzyme assays identify specific deficiencies. Genetic testing confirms the underlying mutation. Early diagnosis is critical for initiating appropriate management.

Treatment Options

Treatment focuses on managing symptoms and slowing disease progression. Enzyme replacement therapy (ERT) may be used for some types. Supportive care includes physical therapy, surgery for skeletal or organ complications, and medications to address pain or neurological symptoms. Hematopoietic stem cell transplantation (HSCT) may be considered in select cases.

Prognosis and Follow-Up

Prognosis varies by type and severity, with some forms causing early mortality and others allowing longer survival with management. Regular follow-up with a multidisciplinary team (e.g., geneticists, neurologists, orthopedists) is essential to monitor organ function, developmental progress, and treatment response. Lifelong care is typically required.

Complications

• Progressive skeletal deformities or joint contractures.
• Cardiac or respiratory complications from organ enlargement.
• Neurological decline or cognitive impairment.
• Vision or hearing loss due to tissue accumulation.

Lifestyle & Prevention

While prevention of the genetic condition is not possible, early intervention can improve outcomes. Families may benefit from genetic counseling to understand inheritance risks. Supportive measures, such as adaptive equipment or educational resources, help manage daily functioning.

When to Seek Professional Help

Seek medical attention if symptoms like developmental delays, unexplained organ enlargement, or skeletal abnormalities appear. Prompt evaluation is crucial for diagnosis and treatment initiation. Genetic counseling is recommended for families with a history of mucopolysaccharidoses.

Tips for Medical Coders

Document the specific type of mucopolysaccharidosis (if known) and any associated complications (e.g., organ involvement, neurological symptoms) to support accurate coding. Ensure clinical documentation aligns with the diagnosis and includes details relevant to the condition's presentation and management.